Antibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MA5-15417 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- PPAR gamma Monoclonal Antibody (3A4A9, 1E6A1)
- Antibody type
- Monoclonal
- Antigen
- Purifed from natural sources
- Description
- MA5-15417 targets PPARG in indirect ELISA, WB applications and shows reactivity with Human samples. The MA5-15417 immunogen is purified recombinant fragment of PPARG (aa170-270) expressed in E. Coli. .
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- 3A4A9, 1E6A1
- Vial size
- 100 µL
- Concentration
- Conc. Not Determined
- Storage
- Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Submitted references Characterization of a pluripotent stem cell-derived matrix with powerful osteoregenerative capabilities.
McNeill EP, Zeitouni S, Pan S, Haskell A, Cesarek M, Tahan D, Clough BH, Krause U, Dobson LK, Garcia M, Kung C, Zhao Q, Saunders WB, Liu F, Kaunas R, Gregory CA
Nature communications 2020 Jun 15;11(1):3025
Nature communications 2020 Jun 15;11(1):3025
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 2 Osteogenesis by ihMSCs is regulated by the cWnt/PPARgamma axis and PPARgamma inhibition increases osteogenesis and matrix productivity. a immunoblotting of ihMSC extracts (replicates of 3) for GSK3beta, beta-catenin, and PPARgamma isoforms in the presence and absence of osteogenic stimulus. ""Supernatant"" and ""Pellet"" represent cytosolic and insoluble extracts respectively. b Densitometry measurements of images in a . c GW9662 exposure under osteogenic conditions causes further upregulation of insoluble beta-catenin and downregulation of soluble GSK3beta. d Densitometry measurements of images in c . e GW9662 exposure under osteogenic conditions causes upregulation of the osteogenic biomarker ALP in ihMSCs. f Culture conditions as e , but mineralization assays with ARS. Representative ARS-stained monolayers are presented (left) with quantification of staining (right). bdl below detectable limits. g Osteogenically enhanced ihMSCs on monolayers generate higher yields of ECM by mass when treated with GW9662. h Protein content in ECM from OEihMSCs and bone marrow-derived OEhMSCs. i Calcium content in ECM recovered from OEihMSCs and BM-OEhMSCs. j GAG content in ECM recovered from OEihMSCs and BM-OEhMSCs treated with GW9662. Statistics: For panels b and d , data presented with means and SD and analyzed by two-tailed Student's t -test. For panels b , d , g - j , n = 3; for f , n = 5; for e , n = 4. Source data are provided as a Source Data file. For panels e - j , data pres